Copeptin: A new marker in cardiology

Journal of Cardiovascular Medicine

Volumn 14, Issue 1, 2013, Pages 19-25

  Morawiec, Beata ^a   Kawecki, Damian ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

acute coronary syndrome; copeptin; marker

Indexed keywords

BIOLOGICAL MARKER; COPEPTIN; TOLVAPTAN; TROPONIN; VASOPRESSIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DIABETES INSIPIDUS; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ELECTROCARDIOGRAM; HEALTH CARE COST; HEART FAILURE; HIGH RISK POPULATION; HORMONE ACTION; HUMAN; KIDNEY DYSFUNCTION; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT CARE; PREDICTIVE VALUE; PROGNOSIS; REFERENCE VALUE; REVIEW; RISK ASSESSMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

BIOLOGICAL MARKERS; CARDIOLOGY; CARDIOVASCULAR DISEASES; GLYCOPEPTIDES; HUMANS; PROGNOSIS;

EID: 84871992438     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3283590d59     Document Type: Review

References (88)

1. Morgenthaler NG. Copeptin: a biomarker of cardiovascular and renal function. Congest Heart Fail 2010; 16 (Suppl 1):S37-S44.
2. Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med 2004; 30:1276-1291. (Pubitemid 38951709)
3. Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005; 46:1785-1791. (Pubitemid 41579797)
4. Robertson GL, Mahr EA, Athar S, Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest 1973; 52:2340-2352.
5. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006; 52:112-119. (Pubitemid 43032474)
6. Rivier C, Vale W. Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature 1983; 305:325-327. (Pubitemid 13010928)
7. Katan M, Morgenthaler N, Widmer I, et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett 2008; 29:341-346.
8. Dünser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003; 107:2313-2319. (Pubitemid 36578501)
9. Morgenthaler NG, Müller B, Struck J, Bergmann A, Redl H, Christ-Crain M. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007; 28:219-226. (Pubitemid 47220835)
10. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005; 26:2500-2504. (Pubitemid 41676723)
11. Katan M, Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly 2010; 140:w13101.
12. Jochberger S, Morgenthaler NG, Mayr VD, et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab 2006; 91:4381-4386. (Pubitemid 44833413)
13. Seligman R, Papassotiriou J, Morgenthaler NG, Meisner M, Teixeira PJ. Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia. Crit Care 2008; 12:R11.
14. Katan M, Morgenthaler NG, Dixit KC, et al. Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay. J Clin Endocrinol Metab 2007; 92:2640-2643. (Pubitemid 47037369)
15. Katan M, Fluri F, Morgenthaler NG, et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann Neurol 2009; 66:799-808.
16. De Marchis GM, Katan M, Weck A, et al. Copeptin and risk stratification in patients with ischaemic stroke and transient attack: the CoRisk Study. Int J Stroke 2012. [Epub ahead of print] doi: 10.1111/j.1747-4949.2011.00762.x.
17. Urwyler SA, Schuetz P, Fluri F, et al. Prognostic value of copeptin: one-year outcome in patients with acute stroke. Stroke 2010; 41:1564-1567.
18. Kleindienst A, Brabant G, Morgenthaler NG, Dixit KC, Parsch H, Buchfelder M. Following brain trauma, copeptin, a stable peptide derived from the AVP precusor, does not reflect osmoregulation but correlates with injury severity. Acta Neurochir Suppl 2010; 106:221-224.
19. Zweifel C, Katan M, Schuetz P, et al. Copeptin is associated with mortality and outcome in patients with acute intracerebral hemorrhage. BMC Neurol 2010; 10:34.
20. Dong XQ, Huang M, Yang SB, Yu WH, Zhang ZY. Copeptin is associated with mortality in patients with traumatic brain injury. J Trauma 2011; 71:1194-1198.
21. Müller B, Morgenthaler N, Stolz D, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007; 37:145-152. (Pubitemid 46066494)
22. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007; 131:1058-1067. (Pubitemid 46608707)
23. Maeder MT, Brutsche MH, Arenja N, et al. Biomarkers and peak oxygen uptake in patients with chronic lung disease. Respiration 2010; 80:543-552.
24. Fenske W, Wanner C, Allolio B, et al. German Diabetes, Dialysis Study Investigators. Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. J Am Soc Nephrol 2011; 22:782-790.
25. Balanescu S, Kopp P, Gaskill MB, Morgenthaler NG, Schindler C, Rutishauser J. Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar states. J Clin Endocrinol Metab 2011; 96:1046-1052.
26. Hoorn EJ, Halperin ML, Zietse R. Diagnostic approach to a patient with hyponatraemia: traditional versus physiology-based options. QJM 2005; 98:529-540. (Pubitemid 41418674)
27. Fenske W, StörkS, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 2009; 94:123-129.
28. Collinson PO, van Dieijen-Visser MP, Pulkki K, et al. Evidence-based laboratory medicine: how well do laboratories follow recommendations and guidelines? The Cardiac Marker Guideline Uptake in Europe (CARMAGUE) study. Clin Chem 2012; 58:305-306.
29. Amini A, Schmidt MH. Syndrome of inappropriate secretion of antidiuretic hormone and hyponatremia after spinal surgery. Neurosurg Focus 2004; 16:E10.
30. Uygun MA, Ozkal E, Acar O, Erongun U. Cerebral salt wasting syndrome. Neurosurg Rev 1996; 19:193-196. (Pubitemid 26264509)
31. Malyszko J, Przybylowski P, Koc-Zorawska E, et al. Copeptin in relation to New York Heart Association class in heart transplant recipients and kidney transplant recipients. Transplant Proc 2010; 42:4259-4262.
32. Hoorn EJ, Geary D, Robb M, Halperin ML, Bohn D. Acute hyponatremia related to intravenous fluid administration in hospitalized children: an observational study. Pediatrics 2004; 113:1279-1284. (Pubitemid 38580693)
33. Wellmann S, Benzing J, Cippà G, et al. High copeptin concentrations in umbilical cord blood after vaginal delivery and birth acidosis. J Clin Endocrinol Metab 2010; 95:5091-5096.
34. Gegenhuber A, Struck J, Dieplinger B, et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 2007; 13: 42-49. (Pubitemid 46343794)
35. Stoiser B, Mörtl D, Hülsmann M, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006; 36:771-778. (Pubitemid 44569965)
36. Khan SQ, Dhillon OS, O'Brien RJ, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 2007; 115:2103-2110. (Pubitemid 46659061)
37. Schaller MD, Nicod P, Nussberger J, et al. Vasopressin in acute myocardial infarct: clinical implications. Schweiz Med Wochenschr 1986; 116:1727-1729. (Pubitemid 17192972)
38. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82:1724-1729. (Pubitemid 20367975)
39. Pope JH, Aufderheide TN, Ruthazer R, et al. Missed diagnoses of acute cardiac ischemia in the emergency department. N Engl J Med 2000; 342:1163-1170. (Pubitemid 30211047)
40. Peacock WF. Will SCUBE1 solve the ischemia marker deficit? J Am Coll Cardiol 2008; 51:2181-2183.
41. Speake D, Terry P. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. First ECG in chest pain. Emerg Med J 2001; 18:61-62.
42. Reichlin T, Hochholzer W, Stelzig C, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 2009; 54:60-68.
43. Meune C, Zuily S, Wahbi K, Claessens YE, Weber S, Chenevier-Gobeaux C. Combination of copeptin and high-sensitivity cardiac troponin T assay in unstable angina and non-ST-segment elevation myocardial infarction: a pilot study. Arch Cardiovasc Dis 2011; 104:4-10.
44. Keller T, Tzikas S, Zeller T, et al. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 2010; 55:2096-2106.
45. Tentzeris I, Jarai R, Farhan S, et al. Complementary role of copeptin and high-sensitivity troponin in predicting outcome in patients with stable chronic heart failure. Eur J Heart Fail 2011; 13:726-733.
46. Lotze U, Lemm H, Heyer A, Müller K. Combined determination of highly sensitive troponin T and copeptin for early exclusion of acute myocardial infarction: first experience in an emergency department of a general hospital. Vasc Health Risk Manag 2011; 7:509-515.
47. Giannitsis E, Kehayova T, Vafaie M, Katus HA. Combined testing of high-sensitivity troponin T and copeptin on presentation at prespecified cutoffs improves rapid rule-out of non-ST-segment elevation myocardial infarction. Clin Chem 2011; 57:1452-1455.
48. Tang WH, Francis GS, Morrow DA, et al., National Academy of Clinical Biochemistry Laboratory Medicine. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007; 116:e99-e109. (Pubitemid 47450268)
49. Chan D, Ng LL. Biomarkers in acute myocardial infarction. BMC Med 2010; 8:34.
50. Freund Y, Chenevier-Gobeaux C, Claessens YE, et al. Concomitant measurement of copeptin and high-sensitivity troponin for fast and reliable rule out of acute myocardial infarction. Intensive Care Med 2012; 38:733-734.
51. Ray P, Charpentier S, Chenevier-Gobeaux C, et al. Combined copeptin and troponin to rule out myocardial infarction in patients with chest pain and a history of coronary artery disease. Am J Emerg Med 2012; 30:440-448.
52. Potocki M, Reichlin T, Thalmann S, et al. Diagnostic and prognostic impact of copeptin and high-sensitivity cardiac troponin T in patients with preexisting coronary artery disease and suspected acute myocardial infarction. Heart 2012; 98:558-565.
53. Karakas M, Januzzi JL Jr, Meyer J, et al. Copeptin does not add diagnostic information to high-sensitivity troponin T in low-to intermediate-risk patients with acute chest pain: results from the rule out myocardial infarction by computed tomography (ROMICAT) study. Clin Chem 2011; 57:1137-1145.
54. Sabatine MS, Morrow DA, de Lemos JA, et al. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation 2012; 125:233-240.
55. Barbato E, Rubattu S, Bartunek J, et al. Human coronary atherosclerosis modulates cardiac natriuretic peptide release. Atherosclerosis 2009; 206:258-264.
56. Barbato E, Bartunek J, Marchitti S, et al. NT-proANP circulating level is a prognostic marker in stable ischemic heart disease. Int J Cardiol 2012; 155:311-312.
57. Barbato E, Bartunek J, Mangiacapra F, et al. Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease. J Am Coll Cardiol 2012; 59:1763-1770.
58. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on myocardial revascularization. Eur Heart J 2010; 31:2501-2555.
59. Melanson SE, Morrow DA, Jarolim P. Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivity. Am J Clin Pathol 2007; 128:282-286. (Pubitemid 47262627)
60. Zipes DP, Libby P, Bonow RO, Braunwald E. Braunwald's Heart Disease. A textbook of cardiovascular medicine. Philadelphia, PA: Elsevier Saunders; 2011.
61. Morgenthaler NG. Die Bedeutung von Copeptin als kardiovaskulärer und renaler Biomarker. Herz 2010; 35 (Suppl III):3-18.
62. Gu YL, Voors AA, Zijlstra F, et al. Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction. Clin Res Cardiol 2011; 100:1069-1076.
63. Dhillon OS, Khan SQ, Narayan HK, et al. Prognostic value of mid-regional pro-adrenomedullin levels taken on admission and discharge in non-ST-elevation myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) II study. J Am Coll Cardiol 2010; 56:125-133.
64. Kelly D, Squire IB, Khan SQ, et al. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J Card Fail 2008; 14:739-745.
65. Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1983; 1:1385-1390. (Pubitemid 13054124)
66. Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl T, Schrier RW. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981; 305:263-266. (Pubitemid 11087371)
67. Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol 2005; 95 (9A):8B-13B. (Pubitemid 40545927)
68. Holmes CL, Landry DW, Granton JT. Science Review: Vasopressin and the cardiovascular system part 2-clinical physiology. Crit Care 2004; 8: 15-23. (Pubitemid 38202135)
69. Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW. Aquaretic effect of lixivaptan, an oral, nonpeptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006; 47:1615-1621.
70. Serradeil-Le Gal C, Wagnon J, Valette G, et al. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res 2002; 139:197-210. (Pubitemid 35460890)
71. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297:1319-1331. (Pubitemid 46513233)
72. Morgenthaler NG, Struck J, Jochberger S, Dünser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008; 19:43-49. (Pubitemid 351317895)
73. Maisel A, Xue Y, Shah K, et al. Increased 90-day mortality in patientswith acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) Study. Circ Heart Fail 2011; 4:613-620.
74. Miller WL, Hartman KA, Hodge DO, et al. Response of novel biomarkers to BNP infusion in patients with decompensated heart failure: a multimarker paradigm. J Cardiovasc Transl Res 2009; 2:526-535.
75. Smith JG, Newton-Cheh C, Almgren P, et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol 2010; 56:1712-1719.
76. Staub D, Morgenthaler NG, Buser C, et al. Use of copeptin in the detection of myocardial ischemia. Clin Chim Acta 2009; 399:69-73.
77. Bhandari SS, Loke I, Davies JE, et al. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 2009; 116:257-263.
78. Voors AA, von Haehling S, Anker SD, et al., OPTIMAAL Investigators. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J 2009; 30:1187-1194.
79. Lin S, Yokoyama H, Rac VE, Brooks SC. Novel biomarkers in diagnosing cardiac ischemia in the emergency department: a systematic review. Resuscitation 2012; 83:684-691.
80. Thygesen K, Alpert JS. White HD on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007; 28:2525-2538.
81. Pulkki K, Suvisaari J, Collinson P, et al. A pilot survey of the use and implementation of cardiac markers in acute coronary syndrome and heart failure across Europe. The CARdiac MArker Guideline Uptake in Europe (CARMAGUE) study. Clin Chem Lab Med 2009; 47:227-234.
82. Wodniecki J, Jacheć W, Szczurek-Katański K, et al. Troponian T: marker restenozy po przezskó rnej plastyce te? tnic wień cowyc u chorych na niestabilna? chorobe? wieńcowa?. Pol Arch Med Wewn 1999; 101: 33-37.
83. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002; 105:1760-1763. (Pubitemid 34408881)
84. Arnauld E, Czernichow P, Fumoux F, Vincent JD. The effects of hypotension and hypovolaemia on the liberation of vasopressin during haemorrhage in the unanaesthetized monkey (Macaca mulatta). Pflugers Arch 1977; 371:193-200. (Pubitemid 8225200)
85. Miller WL, Hartman KA, Grill DE, Struck J, Bergmann A, Jaffe AS. Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure. Heart 2012; 98:389-394.
86. Neuhold S, Huelsmann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol 2008; 52:266-272. (Pubitemid 351957847)
87. Forberg JL, Henriksen LS, Edenbrandt L, Ekelund U. Direct hospital costs of chest pain patients attending the emergency department: a retrospective study. BMC Emerg Med 2006; 6:6.
88. Polanczyk CA, Kuntz KM, Sacks DB, Johnson PA, Lee TH. Emergency department triage strategies for acute chest pain using creatine kinase-MB and troponin I assays: a cost-effectiveness analysis. Ann Intern Med 1999; 131:909-918. (Pubitemid 30005030)